Cellular Membranes Function As a Storage Compartment for Celecoxib

Overview

Journal J Mol Med (Berl)

Specialty General Medicine

Date 2009 Jul 31

PMID 19641861

Citations 7

Authors

Thorsten J Maier

Susanne Schiffmann

Ivonne Wobst

Kerstin Birod

Carlo Angioni

Marika Hoffmann

Jakob J Lopez

Clemens Glaubitz

Dieter Steinhilber

Gerd Geisslinger

Sabine Grosch

Affiliations

Soon will be listed here.

Abstract

Celecoxib is a selective cyclooxygenase-2-(COX-2)-inhibitor used to treat inflammation and pain and prevents colorectal cancer in patients at high doses by affecting several non-COX-2 proteins. However, celecoxib concentrations appropriate to inhibit proliferation or to induce apoptosis in cell culture (up to 100 microM) clearly exceed those in human plasma (up to 10 microM). Therefore, we speculated that celecoxib might accumulate in human cells, which may facilitate the drug's interaction with non-COX-2 proteins. Determination of intracellular celecoxib concentrations by liquid chromatography tandem mass spectrometry gave five- to tenfold higher levels as compared to other coxibs (etoricoxib, valdecoxib, lumiracoxib, and rofecoxib) in different tumor cell types, including human HCA-7 and HCT-116 colon carcinoma cells, BL-41 B lymphocytes, Mono Mac 6 monocytes, and in mouse NIH-3T3 non-tumor fibroblasts. This intracellular accumulation of celecoxib was due to an integration of the drug into cellular phospholipid membranes as demonstrated by nuclear Overhauser spectroscopy/nuclear magnetic resonance. Consequently, celecoxib disturbed the plasma membrane integrity of HCT-116 cells and displayed an increased COX-2-inhibitory potency in HCA-7 cells. The use of other coxibs demonstrated that intracellular accumulation is peculiar of celecoxib. Accumulation of celecoxib in human cells may provide a novel molecular basis for the ability of the drug to interact with non-COX-2 targets in vivo despite comparatively low plasma concentrations.

Citing Articles

Probing the allosteric NBD-TMD crosstalk in the ABC transporter MsbA by solid-state NMR.

Novischi S, Karoly-Lakatos A, Chok K, Bonifer C, Becker-Baldus J, Glaubitz C Commun Biol. 2024; 7(1):43.

PMID: 38182790 PMC: 10770068. DOI: 10.1038/s42003-023-05617-0.

In Vitro Safety, Off-Target and Bioavailability Profile of the Antiviral Compound Silvestrol.

Schiffmann S, Gunne S, Ulshofer T, Henke M, Roser L, Schneider A Pharmaceuticals (Basel). 2022; 15(9).

PMID: 36145307 PMC: 9502993. DOI: 10.3390/ph15091086.

Celecoxib increases lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1.

Schellhorn M, Haustein M, Frank M, Linnebacher M, Hinz B Oncotarget. 2015; 6(36):39342-56.

PMID: 26513172 PMC: 4770776. DOI: 10.18632/oncotarget.5745.

Pharmacological modulation of the AKT/microRNA-199a-5p/CAV1 pathway ameliorates cystic fibrosis lung hyper-inflammation.

Zhang P, Cheng J, Zou S, DSouza A, Koff J, Lu J Nat Commun. 2015; 6:6221.

PMID: 25665524 PMC: 4324503. DOI: 10.1038/ncomms7221.

Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib.

Ramer R, Walther U, Borchert P, Laufer S, Linnebacher M, Hinz B J Lipid Res. 2013; 54(11):3116-29.

PMID: 23943857 PMC: 3793616. DOI: 10.1194/jlr.M042283.

References

Werner U, Werner D, Rau T, Fromm M, Hinz B, Brune K . Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther. 2003; 74(2):130-7. DOI: 10.1016/S0009-9236(03)00120-6. View

Schiffmann S, Maier T, Wobst I, Janssen A, Corban-Wilhelm H, Angioni C . The anti-proliferative potency of celecoxib is not a class effect of coxibs. Biochem Pharmacol. 2008; 76(2):179-87. DOI: 10.1016/j.bcp.2008.04.017. View

Burian M, Geisslinger G . [Clinical pharmacology of the selective COX-2 inhibitors]. Orthopade. 2003; 32(12):1078-87. DOI: 10.1007/s00132-003-0569-0. View

Yamada Y, Yoshimi N, Hirose Y, Hara A, Shimizu M, Kuno T . Suppression of occurrence and advancement of beta-catenin-accumulated crypts, possible premalignant lesions of colon cancer, by selective cyclooxygenase-2 inhibitor, celecoxib. Jpn J Cancer Res. 2001; 92(6):617-23. PMC: 5926764. DOI: 10.1111/j.1349-7006.2001.tb01139.x. View

Paulson S, Kaprak T, Gresk C, Fast D, Baratta M, Burton E . Plasma protein binding of celecoxib in mice, rat, rabbit, dog and human. Biopharm Drug Dispos. 2000; 20(6):293-9. DOI: 10.1002/(sici)1099-081x(199909)20:6<293::aid-bdd188>3.0.co;2-x. View

Zhu J, Huang J, Tseng P, Yang Y, Fowble J, Shiau C . From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res. 2004; 64(12):4309-18. DOI: 10.1158/0008-5472.CAN-03-4063. View

Khanapure S, Garvey D, Janero D, Letts L . Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers. Curr Top Med Chem. 2007; 7(3):311-40. DOI: 10.2174/156802607779941314. View

Schonthal A . Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy. Neurosurg Focus. 2006; 20(4):E21. DOI: 10.3171/foc.2006.20.4.14. View

Johnson A, Hsu A, Lin H, Song X, Chen C . The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks. Biochem J. 2002; 366(Pt 3):831-7. PMC: 1222837. DOI: 10.1042/BJ20020279. View

10.

Silverstein F, Faich G, Goldstein J, Simon L, Pincus T, WHELTON A . Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000; 284(10):1247-55. DOI: 10.1001/jama.284.10.1247. View

11.

Tanaka K, Tomisato W, Hoshino T, Ishihara T, Namba T, Aburaya M . Involvement of intracellular Ca2+ levels in nonsteroidal anti-inflammatory drug-induced apoptosis. J Biol Chem. 2005; 280(35):31059-67. DOI: 10.1074/jbc.M502956200. View

12.

Grosch S, Maier T, Schiffmann S, Geisslinger G . Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst. 2006; 98(11):736-47. DOI: 10.1093/jnci/djj206. View

13.

Ohkawa K, Hatano T, Tsukada Y, Matsuda M . Chemotherapeutic efficacy of the protein-doxorubicin conjugates on multidrug resistant rat hepatoma cell line in vitro. Br J Cancer. 1993; 67(2):274-8. PMC: 1968189. DOI: 10.1038/bjc.1993.52. View

14.

Kuhry J, Fonteneau P, Duportail G, Maechling C, LAUSTRIAT G . TMA-DPH: a suitable fluorescence polarization probe for specific plasma membrane fluidity studies in intact living cells. Cell Biophys. 1983; 5(2):129-40. DOI: 10.1007/BF02796139. View

15.

Palomer A, Cabre F, Pascual J, Campos J, Trujillo M, Entrena A . Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models. J Med Chem. 2002; 45(7):1402-11. DOI: 10.1021/jm010458r. View

16.

Schiffmann S, Sandner J, Schmidt R, Birod K, Wobst I, Schmidt H . The selective COX-2 inhibitor celecoxib modulates sphingolipid synthesis. J Lipid Res. 2008; 50(1):32-40. DOI: 10.1194/jlr.M800122-JLR200. View

17.

Walter M, Jacob R, Day C, Dahlborg R, Weng Y, Mason R . Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis. 2004; 177(2):235-43. DOI: 10.1016/j.atherosclerosis.2004.10.001. View

18.

Bertagnolli M, Eagle C, Zauber A, Redston M, Solomon S, Kim K . Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006; 355(9):873-84. DOI: 10.1056/NEJMoa061355. View

19.

Baron J, Sandler R, Bresalier R, Quan H, Riddell R, Lanas A . A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology. 2006; 131(6):1674-82. DOI: 10.1053/j.gastro.2006.08.079. View

20.

Wobst I, Schiffmann S, Birod K, Maier T, Schmidt R, Angioni C . Dimethylcelecoxib inhibits prostaglandin E2 production. Biochem Pharmacol. 2008; 76(1):62-9. DOI: 10.1016/j.bcp.2008.04.008. View